Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy

RegulatoryapprovedItvismaPositive

AI Analysis

Summary

Novartis gene therapy Itvisma has received European Union approval for the treatment of spinal muscular atrophy, representing a significant regulatory milestone for the company's gene therapy portfolio.

Outcome Details

EU approval for spinal muscular atrophy gene therapy

Importance:8/10

Sentiment:

0.85

gene therapyEU approvalspinal muscular atrophyNovartis

Related Companies

$NVS

Read the original article

Published by Seeking Alpha Healthcare on July 2, 2026 6:20 PM

Read Original